摘要:
The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.
摘要:
The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.
摘要:
The present invention relates to substituted cyclopentene compounds of the general formula I, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use thereof for the production of pharmaceutical preparations.
摘要:
The present invention relates to substituted cyclopentene compounds of the general formula I, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use thereof for the production of pharmaceutical preparations.
摘要:
VGLUT-specific dsRNAs capable of triggering the phenomenon of RNA interference, host cells containing theses dsRNAs, and pharmaceutical compositions containing these dsRNAs, in particular for the treatment of pain and other diseases associated with VGLUT family members.
摘要:
Pharmaceutical formulations are provided and comprise compounds corresponding to formula I, wherein R1, R2, R3 and R4 have the meanings given in the description. Related methods of treating or inhibiting pain and other conditions or disorders are also provided.
摘要:
The invention concerns a nucleic acid molecule which includes a nucleic acid sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide, as well as a host cell which contains this nucleic acid molecule. In addition the invention concerns a polypeptide molecule which functions as chemokine or neuropeptide or contains at least one neuropeptide, as well as fragments thereof which include at least one neuropeptide, and a procedure for the manufacture of the polypeptide molecule or of a fragment thereof. In addition the invention concerns antibodies, demonstration procedures and test-kits as well as pharmaceutical preparations.The purpose on which present invention is based is to make new means available which can be put to use aimed at the diagnosis and/or treatment of diseases which are associated with a defect of the SDF-1 factor or its receptor (CXCR4).